II. Indications
- See GLP-1 Agonist
-
Type II Diabetes Mellitus
- Very effective for weight loss in comorbid Obesity
- May be used in combination with Basal insulin (e.g. Lantus)
-
Insulin deficiency and Insulin Resistance
- Adjunct to Glucophage, Sulfonylureas, Glitazones
- Weight Loss
- At least 50% of weight regained on stopping GLP-1 agents
III. Contraindications
- See GLP-1 Agonist
- Type I Diabetes Mellitus
- Medullary Thyroid Carcinoma (personal or Family History)
- Multiple Endocrine Neoplasia syndrome type 2 (active)
- Concurrent prandial Insulin (Bolus Insulin)
- Basal insulin (e.g. Lantus) may be used
-
Renal Insufficiency (specific for Exenatide in contrast with other GLP-1 Agonists)
- Creatinine Clearance <30 ml/min for Exenatide
- Creatinine Clearance <45 ml/min for Exenatide XR
- Severe Gastrointestinal Diseases or Gastroparesis
- Relative contraindication due to the high Incidence of gastrointestinal side effects with GLP-1 Agonists
IV. Mechanism
- See GLP-1 Agonist
-
Glucagon-Like Peptide 1 (GLP-1) Agonist, an Incretin Mimetic, derived from Gila monster Saliva
- Increases Glucose dependent Insulin secretion
- Inhibits Glucagon secretion
- Delays gastric emptying
- Decreases food intake (improves satiety and decreases appetite)
- Direct effects at the Hypothalamus, Nucleus Accumbens, ventral tegmental areas and Vagus Nerve
V. Medications
- Precautions
- All GLP-1 Agonists are expensive ($600 to $1300 per month in 2024)
- GLP-1 shortages (esp. Semaglutide and Tirzepatide) have resulted in many online resellers
- Buy from only licensed pharmacies (U.S.), and appropriately accredited (e.g. compounding pharmacy)
- Certificates of analysis confirm active ingredient
- Exenatide specific
- Protect medication from light exposure
- Keep refrigerated before first use
- After initial use, keep at room Temperature (above freezing and <78 F (<25 C)
- Caution in impaired Renal Function (and monitor)
- Exenatide is contraindicated with Creatinine Clearance <30 ml/min
- Exenatide ER Weekly is contraindicated with Creatinine Clearance <45 ml/min
- Exenatide (Byetta) Immediate Release
- Lowers Hemoglobin A1C by 1.0%
- Contraindicated in eGFR <30 ml/min
- Prefilled pen holds 30 day supply (60 twice daily doses)
- Pen 5 mcg/dose holds 1.2 ml of 250 mcg/ml
- Pen 10 mcg/dose holds 2.4 ml of 250 mcg/ml
- Exenatide ER Weekly (Bydureon, Bydureon BCise pen)
- Exenatide extended release available as 2 mg doses in prefilled pen (Bydureon) or autoinjector (Bydureon BCise)
- Lowers Hemoglobin A1C by 1.3%
- Contraindicated in eGFR <45 ml/min
- Injected once weekly
- Requires reconstitution from powder before dose
- Less Nausea than Byetta or Victoza, but more injection site reactions than Byetta and Victoza
- Bydureon BCise does not appear more effective than Bydureon (despite hype of consistent drug levels)
VI. Dosing: Adults
- Give subcutaneous doses in the upper arm, Abdomen or thigh (and rotate injection sites)
- Exenatide (Byetta)
- Contraindicated in eGFR <30 ml/min
- Give within 60 minutes of morning and evening meals (with meals at least 6 hours apart)
- Start 5 mcg SQ twice daily
- May increase to 10 mcg SQ twice daily after 1 month, if Blood Sugars not optimized at lower dose
- Exenatide ER Weekly (Bydureon, Bydureon BCise pen)
- Contraindicated in eGFR <45 ml/min
- Dose 2 mg SQ once weekly (regardless of mealtime)
VII. Adverse Effects
- See GLP-1 Agonist
- Adverse effect Prevalence based on original Byetta data
-
Nausea (44%) or Vomiting (13%)
- More with Exenatide than with Exenatide ER Weekly
- Less frequent with Bydureon
- Eat smaller meals and more slowly, stopping before fullness (satiety)
- Consider short-term Ondansetron
- Consider dose reduction until tolerated
- Diarrhea (13%)
- Dizziness (9%)
- Headache (9%)
- Injection site reactions
- More with Exenatide ER Weekly than Exenatide
-
Hypoglycemia
- Alone, GLP-1 Agonists do not significantly increase risk of Hypoglycemia
- Avoid combination with Bolus Insulin (Mealtime Insulin) or Insulin Secretagogues (e.g. Sulfonylureas)
- With Sulfonylurea: 14.4% at 5 mcg, 35.7% at 10 mcg
- With Metformin: 4.5% at 5 mcg, 5.3% at 10 mcg
-
Pancreatitis (occurs with all GLP-1 Agonists)
- Incidence may be as high as 1 in 50 on Byetta for two years
- Singh (2013) JAMA Intern Med 173(7):534-9 [PubMed]
- Gallbladder disease (Cholelithiasis, Cholecystitis, Choledocholithiasis)
- Increased by one in 357 patients over 3 years of medication use
- Increased with longer use, higher dose and when GLP-1 Agonist is used for weight loss
- Faillie (2016) JAMA Intern Med 176(10): 1474-81 +PMID: 27478902 [PubMed]
- Subcutaneous Fat Loss
- Desired weight loss (esp. Semaglutide) may result in loose, sagging skin ("Ozempic face")
- Other serious but uncommon effects (<1%)
- Acute Kidney Injury
- Angioedema
- Suicidality (case reports, FDA is investigating as of 2024)
VIII. Safety
- Unknown safety in Lactation
- Most GLP-1 Agonists have unknown safety in pregnancy (avoid)
- High dose weight loss GLP-1 Agonists (e.g. Saxena, Wegovy) are considered Pregnancy Category X
IX. Efficacy
- No effect on Cardiovascular Risk
- Potency
- Exenatide (Byetta) lowers Hemoglobin A1C by 1.0%
- Contrast with the most potent GLP-1 Agonists that lower A1C 1.5%
- Exenatide ER Weekly (Bydureon, Bydureon BCise pen) lowers Hemoglobin A1C by 1.3%
- Bydureon BCise does not appear more effective than Bydureon (despite hype of consistent drug levels)
- Exenatide (Byetta) lowers Hemoglobin A1C by 1.0%
X. Drug Interactions
- Avoid using 2 Incretins (e.g. Byetta with Januvia) in combination
- Raises cost, risk of Pancreatitis without significant benefit
- (2012) Presc Lett 19(8): 45
- Concurrent prandial Insulin (Bolus Insulin)
- Basal insulin (e.g. Lantus) may be used
- Medications that require rapid gastrointestinal absorption
- Take at least one hour before Immediate release Exenatide (Byetta)
XI. Resources
- Exenatide (DailyMed)
- Exenatide ER: Bydureon BCise (DailyMed)
XII. References
- (2024) Presc Lett 31(7): 38
- (2024) Presc Lett 31(2): 8-9
- (2022) Presc Lett 30(2): 7
- (2019) Presc Lett 26(11):62-3
- (2019) Presc Lett 26(8):46
- (2018) Presc Lett 25(2)
- (2014) Presc Lett 21(12): 69
- (2012) Presc Lett 19(3): 15
- Nordt and Kaucher (2023) EM:Rap 23(9)
- Dungan (2005) Clin Diabetes 23: 56-62 [PubMed]
- Ezzo (2006) Am Fam Physician 73 [PubMed]
- Fineman (2003) Diabetes Care 26:2370-7 [PubMed]
- Jones (2007) Am Fam Physician 75:1831-5 [PubMed]
- Joy (2005) Ann Pharmacol 39:110-8 [PubMed]
- Vaughan (2024) Am Fam Physician 109(4): 333-42 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
byetta (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
BYETTA 10 MCG DOSE PEN INJ | $320.92 per ml | |
BYETTA 5 MCG DOSE PEN INJ | $641.27 per ml | |
bydureon (on 1/19/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
BYDUREON 2 MG PEN INJECT | $181.57 each | |
BYDUREON BCISE 2 MG AUTOINJECT | $220.25 per ml |